Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer

Wenwen Chien, Qiao Yang Sun, Kian Leong Lee, Ling Wen Ding, Peer Wuensche, Lucia A. Torres-Fernandez, Siew Zhuan Tan, Itay Tokatly, Norazean Zaiden, Lorenz Poellinger, Seiichi Mori, Henry Yang, Jeffrey Tyner, H. Phillip Koeffler

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We utilized three tiers of screening to identify novel therapeutic agents for pancreatic cancers. First, we analyzed 14 pancreatic cancer cell lines against a panel of 66 small-molecule kinase inhibitors and dasatinib was the most potent. Second, we performed RNA expression analysis on 3 dasatinib-resistant and 3 dasatinib-sensitive pancreatic cancer cell lines to profile their gene expression. Third, gene profiling data was integrated with the Connectivity Map database to search for potential drugs. Thioridazine was one of the top ranking small molecules with highly negative enrichment. Thioridazine and its family members of phenothiazine including penfluridol caused pancreatic cancer cell death and affected protein expression levels of molecules involved in cell cycle regulation, apoptosis, and multiple kinase activities. This family of drugs causes activation of protein phosphatase 2 (PP2A). The drug FTY-720 (activator of PP2A) induced apoptosis of pancreatic cancer cells. Silencing catalytic unit of PP2A rendered pancreatic cancer cells resistant to penfluridol. Our observations suggest potential therapeutic use of penfluridol or similar agent associated with activation of PP2A in pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)889-905
Number of pages17
JournalMolecular Oncology
Volume9
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Protein Phosphatase 2
Pancreatic Neoplasms
Penfluridol
Neoplasms
Thioridazine
Phosphotransferases
Apoptosis
Cell Line
Therapeutic Uses
Transcriptome
Pharmaceutical Preparations
Cell Cycle
Cell Death
Databases
RNA
Genes

Keywords

  • Dasatinib
  • FTY-720
  • Pancreatic cancer
  • Phenothiazine
  • PP2A

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine

Cite this

Chien, W., Sun, Q. Y., Lee, K. L., Ding, L. W., Wuensche, P., Torres-Fernandez, L. A., ... Koeffler, H. P. (2015). Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Molecular Oncology, 9(4), 889-905. https://doi.org/10.1016/j.molonc.2015.01.002

Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. / Chien, Wenwen; Sun, Qiao Yang; Lee, Kian Leong; Ding, Ling Wen; Wuensche, Peer; Torres-Fernandez, Lucia A.; Tan, Siew Zhuan; Tokatly, Itay; Zaiden, Norazean; Poellinger, Lorenz; Mori, Seiichi; Yang, Henry; Tyner, Jeffrey; Koeffler, H. Phillip.

In: Molecular Oncology, Vol. 9, No. 4, 01.04.2015, p. 889-905.

Research output: Contribution to journalArticle

Chien, W, Sun, QY, Lee, KL, Ding, LW, Wuensche, P, Torres-Fernandez, LA, Tan, SZ, Tokatly, I, Zaiden, N, Poellinger, L, Mori, S, Yang, H, Tyner, J & Koeffler, HP 2015, 'Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer', Molecular Oncology, vol. 9, no. 4, pp. 889-905. https://doi.org/10.1016/j.molonc.2015.01.002
Chien, Wenwen ; Sun, Qiao Yang ; Lee, Kian Leong ; Ding, Ling Wen ; Wuensche, Peer ; Torres-Fernandez, Lucia A. ; Tan, Siew Zhuan ; Tokatly, Itay ; Zaiden, Norazean ; Poellinger, Lorenz ; Mori, Seiichi ; Yang, Henry ; Tyner, Jeffrey ; Koeffler, H. Phillip. / Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. In: Molecular Oncology. 2015 ; Vol. 9, No. 4. pp. 889-905.
@article{f008dfdd85d44d279cdbf804f5ad2f92,
title = "Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer",
abstract = "We utilized three tiers of screening to identify novel therapeutic agents for pancreatic cancers. First, we analyzed 14 pancreatic cancer cell lines against a panel of 66 small-molecule kinase inhibitors and dasatinib was the most potent. Second, we performed RNA expression analysis on 3 dasatinib-resistant and 3 dasatinib-sensitive pancreatic cancer cell lines to profile their gene expression. Third, gene profiling data was integrated with the Connectivity Map database to search for potential drugs. Thioridazine was one of the top ranking small molecules with highly negative enrichment. Thioridazine and its family members of phenothiazine including penfluridol caused pancreatic cancer cell death and affected protein expression levels of molecules involved in cell cycle regulation, apoptosis, and multiple kinase activities. This family of drugs causes activation of protein phosphatase 2 (PP2A). The drug FTY-720 (activator of PP2A) induced apoptosis of pancreatic cancer cells. Silencing catalytic unit of PP2A rendered pancreatic cancer cells resistant to penfluridol. Our observations suggest potential therapeutic use of penfluridol or similar agent associated with activation of PP2A in pancreatic cancers.",
keywords = "Dasatinib, FTY-720, Pancreatic cancer, Phenothiazine, PP2A",
author = "Wenwen Chien and Sun, {Qiao Yang} and Lee, {Kian Leong} and Ding, {Ling Wen} and Peer Wuensche and Torres-Fernandez, {Lucia A.} and Tan, {Siew Zhuan} and Itay Tokatly and Norazean Zaiden and Lorenz Poellinger and Seiichi Mori and Henry Yang and Jeffrey Tyner and Koeffler, {H. Phillip}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.molonc.2015.01.002",
language = "English (US)",
volume = "9",
pages = "889--905",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer

AU - Chien, Wenwen

AU - Sun, Qiao Yang

AU - Lee, Kian Leong

AU - Ding, Ling Wen

AU - Wuensche, Peer

AU - Torres-Fernandez, Lucia A.

AU - Tan, Siew Zhuan

AU - Tokatly, Itay

AU - Zaiden, Norazean

AU - Poellinger, Lorenz

AU - Mori, Seiichi

AU - Yang, Henry

AU - Tyner, Jeffrey

AU - Koeffler, H. Phillip

PY - 2015/4/1

Y1 - 2015/4/1

N2 - We utilized three tiers of screening to identify novel therapeutic agents for pancreatic cancers. First, we analyzed 14 pancreatic cancer cell lines against a panel of 66 small-molecule kinase inhibitors and dasatinib was the most potent. Second, we performed RNA expression analysis on 3 dasatinib-resistant and 3 dasatinib-sensitive pancreatic cancer cell lines to profile their gene expression. Third, gene profiling data was integrated with the Connectivity Map database to search for potential drugs. Thioridazine was one of the top ranking small molecules with highly negative enrichment. Thioridazine and its family members of phenothiazine including penfluridol caused pancreatic cancer cell death and affected protein expression levels of molecules involved in cell cycle regulation, apoptosis, and multiple kinase activities. This family of drugs causes activation of protein phosphatase 2 (PP2A). The drug FTY-720 (activator of PP2A) induced apoptosis of pancreatic cancer cells. Silencing catalytic unit of PP2A rendered pancreatic cancer cells resistant to penfluridol. Our observations suggest potential therapeutic use of penfluridol or similar agent associated with activation of PP2A in pancreatic cancers.

AB - We utilized three tiers of screening to identify novel therapeutic agents for pancreatic cancers. First, we analyzed 14 pancreatic cancer cell lines against a panel of 66 small-molecule kinase inhibitors and dasatinib was the most potent. Second, we performed RNA expression analysis on 3 dasatinib-resistant and 3 dasatinib-sensitive pancreatic cancer cell lines to profile their gene expression. Third, gene profiling data was integrated with the Connectivity Map database to search for potential drugs. Thioridazine was one of the top ranking small molecules with highly negative enrichment. Thioridazine and its family members of phenothiazine including penfluridol caused pancreatic cancer cell death and affected protein expression levels of molecules involved in cell cycle regulation, apoptosis, and multiple kinase activities. This family of drugs causes activation of protein phosphatase 2 (PP2A). The drug FTY-720 (activator of PP2A) induced apoptosis of pancreatic cancer cells. Silencing catalytic unit of PP2A rendered pancreatic cancer cells resistant to penfluridol. Our observations suggest potential therapeutic use of penfluridol or similar agent associated with activation of PP2A in pancreatic cancers.

KW - Dasatinib

KW - FTY-720

KW - Pancreatic cancer

KW - Phenothiazine

KW - PP2A

UR - http://www.scopus.com/inward/record.url?scp=84926406603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926406603&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2015.01.002

DO - 10.1016/j.molonc.2015.01.002

M3 - Article

VL - 9

SP - 889

EP - 905

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 4

ER -